Arginase inhibition improves endothelial function in patients with type 2 diabetes mellitus despite intensive glucose-lowering therapy

Journal of Internal Medicine
Ali MahdiJohn Pernow

Abstract

Arginase is implicated in the pathogenesis behind endothelial dysfunction in type 2 diabetes mellitus (T2DM) by its inhibition of nitric oxide formation. Strict glycaemic control is not sufficient to improve endothelial function or cardiovascular outcomes in patients with T2DM, thus other treatment strategies are needed. We hypothesized that arginase inhibition improves endothelial function beyond glucose-lowering therapy following glucose optimization in patients with poorly controlled T2DM. Endothelial function was evaluated in 16 patients with poorly controlled T2DM (visit 1) and 16 age-matched controls using venous occlusion plethysmography. T2DM patients were re-evaluated (visit 2) after intensive glucose-lowering regimen. Endothelium-dependent (EDV) and -independent (EIDV) vasodilatations were evaluated before and after 120 min intra-arterial infusion of the arginase inhibitor N(ω)-hydroxy-nor-L-arginine (nor-NOHA). HbA1c was reduced from 87 ± 17 (visit 1) to 65 ± 11 mmol mol-1 (visit 2, P < 0.001). Basal EDV, but not EIDV, was significantly lower in patients with T2DM than in healthy subjects (P < 0.05). EDV and EIDV were unaffected by glucose-lowering regimen in patients with T2DM. Arginase inhibition enhanced EDV in T2...Continue Reading

References

Jan 26, 2005·Circulation·Amir Lerman, Andreas M Zeiher
Oct 12, 2007·Diabetes Care·Sangeeta R KashyapRalph A DeFronzo
Oct 31, 2007·Circulation Research·Maritza J RomeroRobert W Caldwell
Jan 31, 2008·Advances in Cardiology·Ricardo J EsperAntonio Paragano
Feb 23, 2008·Clinical and Experimental Pharmacology & Physiology·Karin Jandeleit-DahmAino Soro-Paavonen
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Feb 16, 2010·Archives of Biochemistry and Biophysics·Luigi Di CostanzoDavid W Christianson
Feb 8, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Julia GrönrosJohn Pernow
Sep 6, 2011·European Heart Journal·Ulrich Förstermann, William C Sessa
Nov 9, 2011·Nature Reviews. Endocrinology·Lei ChenPaul Z Zimmet
Feb 8, 2013·Annals of the New York Academy of Sciences·Francesco GiorginoLuigi Laviola
Dec 8, 2014·Diabetologia·Marpadga A ReddyRama Natarajan
Jun 13, 2015·Redox Biology·Michael P HezelEddie Weitzberg
Aug 13, 2015·Nature Reviews. Drug Discovery·Jon O LundbergEddie Weitzberg
May 18, 2016·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Oskar KövameesJohn Pernow
Nov 5, 2016·The Journal of Clinical Endocrinology and Metabolism·Oskar KövameesJohn Pernow
Oct 20, 2017·Cardiovascular Research·Anil BhattaRobert W Caldwell

❮ Previous
Next ❯

Citations

Nov 30, 2018·Aging·Zhichao ZhouJohn Pernow
Nov 21, 2019·Clinical Hemorheology and Microcirculation·Bernhard WernlyChristian Jung
Apr 17, 2020·International Journal of Molecular Sciences·Tommaso Gori
Jun 15, 2019·Cardiovascular Research·John PernowZhichao Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.